Drugs targeting the apoptosis pathway (such as PTL) may also serve as an effective strategy for NSCLC therapy, and might play vital roles in minimizing adverse reactions, maximizing clinical efficacy, and helping to increase the quality of life for patients. This evidence concerns the gene PNLIP and non-small cell lung carcinoma.